TY - JOUR
T1 - Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe
T2 - the PanCareSurFup study
AU - Heymer, Emma J.
AU - Hawkins, Michael M.
AU - Winter, David L.
AU - Teepen, Jop C.
AU - Sunguc, Ceren
AU - Ronckers, Cécile M.
AU - Allodji, Rodrigue S.
AU - Alessi, Daniela
AU - Sugden, Elaine
AU - Belle, Fabiën N.
AU - Bagnasco, Francesca
AU - Byrne, Julianne
AU - Bárdi, Edit
AU - Garwicz, Stanislaw
AU - Grabow, Desiree
AU - Jankovic, Momcilo
AU - Kaatsch, Peter
AU - Kaiser, Melanie
AU - Michel, Gisela
AU - Schindera, Christina
AU - Haddy, Nadia
AU - Journy, Neige
AU - Česen Mazić, Maja
AU - Skinner, Roderick
AU - Kok, Judith L.
AU - Gunnes, Maria W.
AU - Wiebe, Thomas
AU - Sacerdote, Carlotta
AU - Maule, Milena M.
AU - Terenziani, Monica
AU - Jakab, Zsuzsanna
AU - Winther, Jeanette F.
AU - Lähteenmäki, Päivi M.
AU - Zadravec Zaletel, Lorna
AU - Haupt, Riccardo
AU - Kuehni, Claudia E.
AU - Kremer, Leontien C.
AU - de Vathaire, Florent
AU - Hjorth, Lars
AU - Reulen, Raoul C.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/4/6
Y1 - 2024/4/6
N2 - Background: Childhood cancer survivors are at risk of subsequent gliomas and meningiomas, but the risks beyond age 40 years are uncertain. We quantified these risks in the largest ever cohort. Methods: Using data from 69,460 5-year childhood cancer survivors (diagnosed 1940–2008), across Europe, standardized incidence ratios (SIRs) and cumulative incidence were calculated. Results: In total, 279 glioma and 761 meningioma were identified. CNS tumour (SIR: 16.2, 95% CI: 13.7, 19.2) and leukaemia (SIR: 11.2, 95% CI: 8.8, 14.2) survivors were at greatest risk of glioma. The SIR for CNS tumour survivors was still 4.3-fold after age 50 (95% CI: 1.9, 9.6), and for leukaemia survivors still 10.2-fold after age 40 (95% CI: 4.9, 21.4). Following cranial radiotherapy (CRT), the cumulative incidence of a glioma in CNS tumour survivors was 2.7%, 3.7% and 5.0% by ages 40, 50 and 60, respectively, whilst for leukaemia this was 1.2% and 1.7% by ages 40 and 50. The cumulative incidence of a meningioma after CRT in CNS tumour survivors doubled from 5.9% to 12.5% between ages 40 and 60, and in leukaemia survivors increased from 5.8% to 10.2% between ages 40 and 50. Discussion: Clinicians following up survivors should be aware that the substantial risks of meningioma and glioma following CRT are sustained beyond age 40 and be vigilant for symptoms.
AB - Background: Childhood cancer survivors are at risk of subsequent gliomas and meningiomas, but the risks beyond age 40 years are uncertain. We quantified these risks in the largest ever cohort. Methods: Using data from 69,460 5-year childhood cancer survivors (diagnosed 1940–2008), across Europe, standardized incidence ratios (SIRs) and cumulative incidence were calculated. Results: In total, 279 glioma and 761 meningioma were identified. CNS tumour (SIR: 16.2, 95% CI: 13.7, 19.2) and leukaemia (SIR: 11.2, 95% CI: 8.8, 14.2) survivors were at greatest risk of glioma. The SIR for CNS tumour survivors was still 4.3-fold after age 50 (95% CI: 1.9, 9.6), and for leukaemia survivors still 10.2-fold after age 40 (95% CI: 4.9, 21.4). Following cranial radiotherapy (CRT), the cumulative incidence of a glioma in CNS tumour survivors was 2.7%, 3.7% and 5.0% by ages 40, 50 and 60, respectively, whilst for leukaemia this was 1.2% and 1.7% by ages 40 and 50. The cumulative incidence of a meningioma after CRT in CNS tumour survivors doubled from 5.9% to 12.5% between ages 40 and 60, and in leukaemia survivors increased from 5.8% to 10.2% between ages 40 and 50. Discussion: Clinicians following up survivors should be aware that the substantial risks of meningioma and glioma following CRT are sustained beyond age 40 and be vigilant for symptoms.
UR - http://www.scopus.com/inward/record.url?scp=85182705638&partnerID=8YFLogxK
U2 - 10.1038/s41416-024-02577-y
DO - 10.1038/s41416-024-02577-y
M3 - Article
AN - SCOPUS:85182705638
SN - 0007-0920
VL - 130
SP - 976
EP - 986
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 6
ER -